SLC9A1 and neoplasm: Next, we exposed 4T1 and TS/A cells for 96 h to the NHE‐1 inhibitor EIPA or to the PPI ESO alone or together, or in combination with Cis, at the doses and times previously selected for the treatment of tumor cell lines (Figures S1 and S2).8, 36